U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. Integrative Proteogenomics for Elucidation of Tumor-specific Cell Surface Proteomes in Ultra-rare Cancers
  1. Oncology Center of Excellence

Integrative Proteogenomics for Elucidation of Tumor-specific Cell Surface Proteomes in Ultra-rare Cancers

External Institution: Memorial Sloan Kettering Cancer Center 

External Collaborators: Alex Kentsis, MD, PhD; Andrew McPherson, PhD

FDA Collaborators: Jeffery Summers, MD; Michael Norcross, PhD; Devaveena Dey, PhD; Martha Donoghue, MD; Wenming Xiao, PhD; Kristin Wessel, MD

Project Start Date: September 2024

Regulatory Science Challenge

Sarcomas such as rhabdoid tumors and desmoplastic small round cell tumors (DSRCT) are ultra-rare cancers. Unfortunately, these sarcomas frequently do not respond to existing treatments. The rarity of these cancers and the limitations of current research methods have led to an incomplete understanding of the biological processes and molecular mechanisms underlying this disease. Therefore, there is a high unmet need for research to identify new therapeutic targets in sarcomas.

Project Description and Goals

The main goal of the project is to apply and integrate innovative genomics and proteomics technologies, such as long-read DNA sequencing, RNA sequencing, and high-resolution mass spectrometry to create detailed maps of proteins on the surface of rhabdoid and DSRCT tumors using patient samples. This project will contribute to the NIH Cancer Data Science Initiative vision for a shared cancer research database and ultimately advance precision medicine for ultra-rare cancers by uncovering new therapeutic targets. 

Further Information

Back to Top